Sign in

You're signed outSign in or to get full access.

Sarissa Capital Management LP

CIK:0001577524
Hedge Fund
$559M AUM
7 holdings
Greenwich, CT, United States
Founded:2012
10 employees
Latest filing:Jun 30, 2025

Sarissa Capital Management LP is a hedge fund headquartered in Greenwich, Connecticut, United States. Founded in 2012 by Alex Denner, Sarissa specializes in healthcare and biotechnology investments, employing a team of approximately 10 professionals. The firm is known for its activist approach and focuses on delivering value to institutional and sophisticated investors through deep sector expertise and strategic engagement.

Investment Strategy

Sarissa Capital Management LP primarily targets healthcare and biotechnology companies, leveraging activist investment strategies. The firm seeks undervalued opportunities where it can engage with management and drive strategic or operational improvements. Its investment process is grounded in fundamental research and value creation through active governance initiatives, seeking to maximize shareholder returns in select life sciences sectors.

Latest 13F Filing Activity

Sarissa Capital Management LP filed their most recent 13F report on Jun 30, 2025 disclosing 7 equity positions with a total 13F market value of $154M. The fund increased holdings in Amarin Corp. PLC, Innoviva Inc., Neurocrine Biosciences Inc. among other positions. Sarissa Capital Management LP reduced exposure to Ironwood Pharmaceuticals Inc., Amarin Corp. PLC, Cytokinetics Inc. among others.

Top Buys
A
AMRNAMARIN CORP PLC
+$20.2M
I
IRWDIRONWOOD PHARMACEUTICALS INC
-$12.7M
I
INVAINNOVIVA INC
+$5.5M
C
CYTKCYTOKINETICS INC
-$4.7M
N
NBIXNEUROCRINE BIOSCIENCES INC
+$3.9M
Top Sells
A
AMRNAMARIN CORP PLC
+$20.2M
I
IRWDIRONWOOD PHARMACEUTICALS INC
-$12.7M
A
AMRNAMARIN CORP PLC
-$11.1M
I
INVAINNOVIVA INC
+$5.5M
C
CYTKCYTOKINETICS INC
-$4.7M

Top Holdings

I
INVAINNOVIVA INC
+36.6%$56.6M
N
NBIXNEUROCRINE BIOSCIENCES INC
+24.7%$38.1M
A
AMRNAMARIN CORP PLC
+13.1%$20.2M
C
CYTKCYTOKINETICS INC
+12.6%$19.4M
I
IRWDIRONWOOD PHARMACEUTICALS INC
+7.4%$11.4M

Equity Positions (7)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
INNOVIVA INC36.64%$56.6M2,816,022$12.87$20.09+$5.5M
NEUROCRINE BIOSCIENCES INC24.68%$38.1M303,151$112.85$125.69+$3.9M
AMARIN CORP PLC13.05%$20.2M1,242,527$16.22$16.22+$20.2M
CYTOKINETICS INC12.59%$19.4M588,357$59.65$33.04-$4.7M
IRONWOOD PHARMACEUTICALS INC7.40%$11.4M15,919,435$11.97$0.72-$12.7M

Industry Allocation

PHARMACEUTICAL PREPARATIONS
+70.6%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+24.3%
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
+5.2%

Investment Team (5)

NameRoleLocationLinkedIn
Dave Finley
Dave Finley
Managing PartnerBoston, MA , United States
Odysseas Kostas
Odysseas Kostas
Senior Managing DirectorGreenwich, CT , United States
Simos Simeonidis
Simos Simeonidis
Senior AnalystNew York, NY , United States
M
Mark DiPaolo
Senior PartnerGreenwich, CT , United States
Patrice Bonfiglio
Patrice Bonfiglio
PresidentStamford, CT , United States